Related Experiment Video
Updated: Oct 19, 2025
A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Vascular Ehlers-Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches
Chanika Assavarittirong1, Tsz Yuen Au1, Phu Vinh Nguyen2
1From the Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland.
Insights
Vascular Ehlers-Danlos syndrome (vEDS) management shows promise with new discoveries. Research indicates potential treatments targeting COL3A1 gene variants and enhancing collagen production for vascular health.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Medicine
Background:
- Vascular Ehlers-Danlos syndrome (vEDS) is a rare, fatal autosomal dominant disorder.
- It is characterized by vascular rupture risk due to pathogenic COL3A1 gene variants.
- Type III collagen, encoded by COL3A1, is crucial for vascular wall integrity.
Purpose of the Study:
- To review recent advancements in understanding and managing vEDS.
- To explore novel therapeutic strategies targeting the genetic basis of vEDS.
- To identify potential pathways for enhancing type III collagen synthesis and vascular strength.
Main Methods:
- Review of recent preclinical studies and molecular findings related to vEDS.
- Analysis of therapeutic interventions in vEDS models, including pharmacological and genetic approaches.
- Investigation of molecular mechanisms regulating COL3A1 expression and type III collagen production.
Main Results:
- Celiprolol treatment improved thoracic aorta biomechanical strength in vEDS mice.
- Small interfering RNAs (siRNA) demonstrated effective silencing of pathogenic COL3A1 alleles.
- Lysyl oxidase and Nanog were identified as regulators enhancing wild-type COL3A1 expression and collagen synthesis.
Conclusions:
- Recent discoveries offer potential new avenues for vEDS management.
- Targeting COL3A1 gene expression and collagen synthesis shows therapeutic promise.
- Further research is needed to translate these findings into clinical applications and personalized treatments for vEDS patients.
Abstract:
Vascular Ehlers-Danlos syndrome (vEDS) is a rare autosomal dominant genetic disorder. It is the most fatal among all types of EDS. In addition to typical EDS characteristics, vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the COL3A1 gene, which encodes type III collagen. Type III collagen is a major component of humans' vascular walls. The management of this disease is possible; however, there is no cure as of present. Recently, discoveries with potential impact on the management of vEDS have been elucidated. Mice with vEDS traits treated with a beta-blocker celiprolol showed significant improvements in their thoracic aorta biomechanical strength. Moreover, it has been demonstrated that the specifically designed small interference RNAs (siRNA) can effectively silence the pathogenic variant allele. To enhance the normal allele expression, an intracellularly expressed lysyl oxidase is shown to regulate the transcription rate of the COL3A1 promoter. Similarly, an embryonic homeobox transcription factor Nanog upregulates the wild-type COL3A1 expression through activation of the transforming growth factor-beta pathway, which increases type III collagen synthesis. Despite numerous advancements, more studies are to be performed to incorporate these discoveries into clinical settings, and eventually, more personalized treatments can be created.
More Related Videos
Related Concept Videos
01:20Overview of the Vascular System
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:26Varicose Veins I: Introduction
01:24Regulation of Angiogenesis and Blood Supply
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:30Venous Thrombosis I: Introduction